Krystal Biotech reports $96mln 2Q VYJUVEK revenue, $820.8mln cash.

• Krystal Biotech reports $96m in 2Q VYJUVEK revenue, $525.4m since launch. • VYJUVEK approved in Japan for DEB treatment from birth. • Company ends Q2 with $820.8m in cash and investments. • CEO expects global expansion and key readouts in lung and eye treatments.

Krystal Biotech (NASDAQ: KRYS) reported robust financial results for the second quarter ending June 30, 2025, highlighting significant milestones and revenue growth. The company achieved $96.0 million in VYJUVEK revenue and a strong cash position of $820.8 million. VYJUVEK, a non-invasive topical gene therapy, saw $525.4 million in total revenue since its launch in the third quarter of 2023. The quarter also marked the approval of VYJUVEK in Japan for the treatment of Dystrophic Epidermolysis Bullosa (DEB) from birth [1].

Krystal Biotech's financial performance was bolstered by impressive metrics, including a 93% gross margin and 82% patient compliance. The company's net income reached $38.3 million, translating to $1.33 per share. The CEO, Krish S. Krishnan, expressed optimism about the company's global expansion, stating, "With the approval of VYJUVEK in Europe and Japan, we are on the cusp of a global expansion that will build on our U.S. sales momentum and dramatically expand VYJUVEK access to DEB patients around the world" [1].

The company's pipeline continues to advance, with key trial progressions in cystic fibrosis (CF), alpha-1 antitrypsin deficiency (AATD), corneal treatments, and solid tumors. Planned European launches in Germany (Q3) and France (Q4) further underscore Krystal Biotech's commitment to expanding VYJUVEK's reach globally [1].

Krystal Biotech's strong balance sheet, ending the quarter with $820.8 million in cash and investments, provides a solid foundation for future growth and research. The company's financial guidance for the year remains focused on its non-GAAP combined R&D and SG&A expense, which excludes stock-based compensation [1].

The company will host an investor webcast on August 4, 2025, at 8:30 am ET, providing further details on its financial performance and future plans. Investors can access the live webcast at: [https://www.webcaster4.com/Webcast/Page/3018/52772](https://www.webcaster4.com/Webcast/Page/3018/52772) [1].

References:
[1] https://www.stocktitan.net/news/KRYS/krystal-biotech-announces-second-quarter-2025-financial-and-czc3ui4ednlh.html